FDA Peptide Regulations: What Changed and What's Coming

A Regulatory System Under Pressure

The FDA's regulation of peptides sits at the intersection of several competing pressures: pharmaceutical innovation, public health protection, patient access, and industry economics. Over the past several years, a series of regulatory actions has reshaped the peptide landscape in ways that affect patients, compounding pharmacies, physicians, and researchers. Understanding this timeline is essential for anyone involved in the peptide space.^[1]

The Bulk Drug Substance Framework

The legal foundation for peptide compounding rests on the distinction between "bulk drug substances" that compounding pharmacies are permitted to use and those that are restricted. The FDA maintains two key lists under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act):

• 503A pharmacies (traditional compounding pharmacies) compound medications pursuant to individual patient prescriptions. They are primarily regulated by state boards of pharmacy but must use bulk drug substances that are components of FDA-approved drugs, are listed in the USP, or appear on a list established by the FDA through a formal rulemaking process.
• 503B outsourcing facilities can compound without individual prescriptions and distribute products in larger quantities, but they must register with the FDA, are subject to FDA inspection, and must comply with current good manufacturing practices (cGMP). They may compound using bulk drug substances on the FDA's established list.^[2]

The FDA's Bulk Drug Substance (BDS) nomination and review process determines which compounds compounding pharmacies can legally use. This process has been contentious, with the FDA reviewing nominated substances for safety, efficacy, and historical use, while patient advocacy groups and compounding pharmacies argue for broader access.

Timeline of Key Regulatory Events

2013: Drug Quality and Security Act (DQSA)

The DQSA was enacted in response to the 2012 New England Compounding Center (NECC) fungal meningitis outbreak, which killed 76 people and sickened hundreds. The Act created the 503B outsourcing facility category, established new federal oversight mechanisms, and began the process of defining which substances could be compounded.^[3]

2020-2022: Bulk Drug Substance Category Reviews

The FDA conducted a systematic review of nominated bulk drug substances, evaluating each for clinical need, safety profile, and historical use. Several peptides were evaluated, with some receiving favorable determinations and others being flagged for further review or denial. This process was criticized by some stakeholders as too slow and by others as too permissive.

2023: Semaglutide Shortage Declaration

The FDA added semaglutide to its drug shortage list, a determination that had significant downstream effects. Under Section 503A, compounding pharmacies can compound copies of commercially available drugs during declared shortages. This shortage designation effectively opened the door for widespread compounding of semaglutide by licensed pharmacies, dramatically expanding patient access at lower price points.

The shortage resulted from unprecedented demand driven by clinical data supporting GLP-1 receptor agonists for weight management, combined with manufacturing capacity limitations at the branded manufacturers.^[4]

2024: Tirzepatide Shortage and Compounding Expansion

Similar shortage dynamics affected tirzepatide, with the FDA shortage designation again enabling compounding pharmacy production. The combined semaglutide and tirzepatide compounding market grew rapidly, with hundreds of compounding pharmacies adding these products to their catalogs.

2024: FDA Enforcement Actions

Throughout 2024, the FDA issued multiple warning letters and took enforcement actions against entities selling peptides outside legitimate channels. These actions targeted both gray market vendors selling "research use only" products and compounding facilities that were found to be operating outside their legal authority. Notable areas of enforcement included companies selling semaglutide products that did not meet compounding pharmacy requirements and vendors marketing peptides with unsubstantiated therapeutic claims.

2024-2025: Shortage Resolution Considerations

As branded manufacturers increased production capacity, the question of when (and whether) semaglutide and tirzepatide shortages would be officially resolved became a major regulatory flashpoint. Resolution of the shortage would remove the legal basis for 503A pharmacies to compound copies of these drugs, potentially affecting hundreds of thousands of patients who had begun treatment through compounded products.

The Category System for Peptides

The FDA's approach to peptide regulation has evolved to categorize different compounds based on their risk-benefit profile:

• FDA-approved peptides: Compounds with full New Drug Application (NDA) or Biologics License Application (BLA) approval (e.g., branded semaglutide, tirzepatide). These can only be compounded during declared shortages or if not "essentially a copy" of the commercial product.
• Compoundable peptides: Compounds on the FDA's positive list or components of approved drugs that compounding pharmacies can legally produce with a valid prescription.
• Nominated but under review: Compounds that have been nominated for the bulk drug substance list but have not yet received a final determination.
• Denied or restricted: Compounds that the FDA has determined should not be compounded, either due to safety concerns or because adequate commercial alternatives exist.

HHS and Policy Signals

The regulatory environment is further complicated by signals from the Department of Health and Human Services (HHS) and political appointees. Policy positions on drug pricing, patient access, and compounding pharmacy regulation have varied across administrations and can shift with new appointments.

Recent signals from HHS leadership have included statements about increasing competition in the pharmaceutical market, protecting patient access to compounded medications, and reforming drug pricing. How these broad policy goals translate into specific regulatory actions remains to be seen, but they create an environment of uncertainty for all stakeholders.^[5]

State-Level Regulatory Changes

While federal regulation sets the baseline, states have significant authority over compounding pharmacy regulation and have been increasingly active in this space:

• Telehealth prescribing: Several states have enacted or modified laws governing telehealth prescriptions for peptides and weight management medications. Some states have tightened requirements, requiring in-person visits before prescribing, while others have maintained pandemic-era telehealth flexibility.
• Compounding pharmacy oversight: State boards of pharmacy vary significantly in their inspection frequency, enforcement vigor, and standards for compounding operations. This creates a patchwork of regulatory quality across the country.
• Consumer protection: Some states have enacted specific consumer protection measures targeting the marketing of compounded medications, including requirements for disclosure about the differences between compounded and FDA-approved products.
• Gray market enforcement: A growing number of states have taken enforcement action against vendors selling peptides as "research chemicals" within their borders, with some states passing specific legislation to address this practice.

What to Watch For

The peptide regulatory landscape will continue to evolve. Key developments to monitor include:

• FDA decisions on bulk drug substance nominations for additional peptides
• Resolution (or continuation) of GLP-1 receptor agonist shortage designations
• Federal legislation addressing drug pricing and compounding pharmacy access
• State-level telehealth and compounding regulations
• FDA enforcement trends against gray market vendors
• Court challenges to FDA regulatory authority in the compounding space

Staying informed about these developments is not optional for anyone involved in the peptide space — whether as a patient, provider, or industry participant. The rules are changing, and the consequences of non-compliance are increasing.^[6]